BOLT

Bolt Biotherapeutics, Inc. (BOLT) | Rumor.io

Bolt Biotherapeutics

BOLT

Attention (50-day avg)0%

Attention rank (50-day avg)#3,123

Bullish sentiment (50-day avg)90%

Price to earnings ratio-0.19

Market capitalization6.7M

Earnings per share-16.5

Dividend yield (TTM)—

Revenue (annual)7.7M

Net income (annual)-33.4M

Social

What share of all stock conversation is about BOLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Oct 2

Bolt Biotherapeutics, Inc. (BOLT) has extended its cash runway into 2027 and provided an update on its BDC-4182 program, with initial data expected in 3Q 2026.
The company has reduced its workforce by approximately 50% to reduce cash burn and advance its ISAC pipeline, which includes collaborations with Genmab and Toray.
BOLT's shares have fallen on news of the workforce reduction and delays in its cancer therapy trial, with some investors speculating that the company may not secure a partnership for its BDC-3042 asset.

Generated by AI

Sentiment

Of the messages about BOLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +13.33	97.68% +24.85
Bearish	—	0% 0	0% -13.33	2.32% -24.85

Bullish· Dec 13

Bolt Biotherapeutics, Inc. is positioning itself for growth with its EV push, potentially leading to significant stock gains.

Bearish· Dec 6

$BOLT's poor performance in premarket and low volume may indicate a further decline during market hours.
The company's ESMO presentation was a "nuthing-burger" and there's "not much to look forward to soon", suggesting a bleak outlook.
$BOLT's cash reserves and investments are insufficient to support its current stock price, indicating a potential fire sale.

Generated by AI

Topics

Of the messages about BOLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	74.77%
Analysts	—	—	—	5.41%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	1.5%
Technical Analysis	—	—	—	18.32%

Dec 16

Bolt Biotherapeutics, Inc. ($BOLT) was granted a US patent for "THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF", which aims to address a need for new compositions to treat inaccessible tumors and expand cancer treatment options.
Bolt Metals Corp. ($BOLT) owns significant reserves of critical metals, including 10.4% Sb at New Britain and 4.7% Cu and 2.3 g/t Au at Soap Gulch, with a market capitalization of $7.5M CAD.
The US has only 5% of its annual antimony demand covered by stockpiles, making companies like Bolt Metals Corp. ($BOLT) strategic players in the critical metals space.

Generated by AI

Community

Of the messages about BOLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	42.86%	18.11%
Newcomers	—	100%	57.14%	81.89%

Regulars· Dec 6

Bolt Biotherapeutics reported interim Phase 1/2 data for BDC-1001, demonstrating a safe and well-tolerated profile and emerging clinical activity at the ESMO Immuno-Oncology Congress 2021.
Stifel Nicolaus raised Bolt Biotherapeutics' price target to $34 from $19, maintaining a buy rating.
The stock's recent performance is attributed to the ESMO data, which failed to meet expectations, leading to a decline in the company's valuation.

Newcomers· Dec 16

Newcomers to Bolt Metals Corp. are highlighting its potential to provide a North American alternative to Chinese-controlled antimony production.
The company's Soap Gulch mine has historic copper grades of 4.7%, making it a promising player in the electrification revolution driven by copper's critical role in EVs and green energy.
With a market cap of $7.5M CAD, newcomers are positioning Bolt Metals Corp. for major gains as the company's strategic play in the copper market unfolds.

Generated by AI

News

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to...

29d agoBarchart.com

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

1mo agoca.finance.yahoo.com

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

1mo agoYahoo Finance

Also Discussed

Investors talking about BOLT also mention

#	Name	Attention
1	Mainz Biomed N.V.MYNZ	0%new
2	MicroCloud Hologram Inc.HOLO	0%0
3	ImageneBio, Inc.IKNA	0%0
4	Bright Minds Biosciences Inc.DRUG	0%new
5	RPHM - Reneo Pharmaceuticals, Inc.	——
6	Banco Bradesco S.A. ADRBBD	0.01%+0.01
7	CMRX - Chimerix, Inc.	——
8	SoundHound AI, Inc. Class A Common StockSOUN	0.02%0
9	OMIC - Singular Genomics Systems, Inc.	——
10	Columbia Select Technology ETFSEMI	0%new

Bolt Biotherapeutics, Inc.

Healthcare
Biotechnology

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. The company’s current programs center on novel approaches that engage the immune system, including its Boltbody Immune-Stimulating Antibody Conjugate platform and myeloid-directed antibodies designed to activate tumor-fighting immune responses. Its pipeline includes candidates that target specific cancer markers and tumor biology, reflecting a focus on precision immuno-oncology rather than broad, traditional chemotherapy. Bolt Biotherapeutics works within the biotechnology and cancer treatment markets, where it contributes to the development of targeted therapies intended to address unmet needs in oncology. Based in Redwood City, California, the company operates as a public biotech enterprise with a research and development model centered on advancing experimental cancer treatments through clinical evaluation.

Website

Location

900 Chesapeake Drive

Redwood City, CA, 94063

United States

Social

What share of all stock conversation is about BOLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Oct 2

Bolt Biotherapeutics, Inc. (BOLT) has extended its cash runway into 2027 and provided an update on its BDC-4182 program, with initial data expected in 3Q 2026.
The company has reduced its workforce by approximately 50% to reduce cash burn and advance its ISAC pipeline, which includes collaborations with Genmab and Toray.
BOLT's shares have fallen on news of the workforce reduction and delays in its cancer therapy trial, with some investors speculating that the company may not secure a partnership for its BDC-3042 asset.

Generated by AI

Sentiment

Of the messages about BOLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +13.33	97.68% +24.85
Bearish	—	0% 0	0% -13.33	2.32% -24.85

Bullish· Dec 13

Bolt Biotherapeutics, Inc. is positioning itself for growth with its EV push, potentially leading to significant stock gains.

Bearish· Dec 6

$BOLT's poor performance in premarket and low volume may indicate a further decline during market hours.
The company's ESMO presentation was a "nuthing-burger" and there's "not much to look forward to soon", suggesting a bleak outlook.
$BOLT's cash reserves and investments are insufficient to support its current stock price, indicating a potential fire sale.

Generated by AI

Topics

Of the messages about BOLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	74.77%
Analysts	—	—	—	5.41%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	1.5%
Technical Analysis	—	—	—	18.32%

Dec 16

Bolt Biotherapeutics, Inc. ($BOLT) was granted a US patent for "THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF", which aims to address a need for new compositions to treat inaccessible tumors and expand cancer treatment options.
Bolt Metals Corp. ($BOLT) owns significant reserves of critical metals, including 10.4% Sb at New Britain and 4.7% Cu and 2.3 g/t Au at Soap Gulch, with a market capitalization of $7.5M CAD.
The US has only 5% of its annual antimony demand covered by stockpiles, making companies like Bolt Metals Corp. ($BOLT) strategic players in the critical metals space.

Generated by AI

Community

Of the messages about BOLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	42.86%	18.11%
Newcomers	—	100%	57.14%	81.89%

Regulars· Dec 6

Bolt Biotherapeutics reported interim Phase 1/2 data for BDC-1001, demonstrating a safe and well-tolerated profile and emerging clinical activity at the ESMO Immuno-Oncology Congress 2021.
Stifel Nicolaus raised Bolt Biotherapeutics' price target to $34 from $19, maintaining a buy rating.
The stock's recent performance is attributed to the ESMO data, which failed to meet expectations, leading to a decline in the company's valuation.

Newcomers· Dec 16

Newcomers to Bolt Metals Corp. are highlighting its potential to provide a North American alternative to Chinese-controlled antimony production.
The company's Soap Gulch mine has historic copper grades of 4.7%, making it a promising player in the electrification revolution driven by copper's critical role in EVs and green energy.
With a market cap of $7.5M CAD, newcomers are positioning Bolt Metals Corp. for major gains as the company's strategic play in the copper market unfolds.

Generated by AI

Bolt Biotherapeutics

Social

Oct 2

Bullish· Dec 13

Bearish· Dec 6

Dec 16

Regulars· Dec 6

Newcomers· Dec 16

Bolt Biotherapeutics CEO Quinn sells $58,402 in stock

Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares

Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Bolt Biotherapeutics, Inc.

Company Information

Location

Bolt Biotherapeutics CEO Quinn sells $58,402 in stock

Bolt Biotherapeutics senior VP Nemec sells $26,072 in shares

Bolt Biotherapeutics COO Grant Yonehiro sells $43,806 in company shares

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Social

Oct 2

Bullish· Dec 13

Bearish· Dec 6

Dec 16

Regulars· Dec 6

Newcomers· Dec 16